MX2015006720A - D-metadona para el tratamiento de sintomas psiquiatricos. - Google Patents
D-metadona para el tratamiento de sintomas psiquiatricos.Info
- Publication number
- MX2015006720A MX2015006720A MX2015006720A MX2015006720A MX2015006720A MX 2015006720 A MX2015006720 A MX 2015006720A MX 2015006720 A MX2015006720 A MX 2015006720A MX 2015006720 A MX2015006720 A MX 2015006720A MX 2015006720 A MX2015006720 A MX 2015006720A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- methadone
- psychiatric symptoms
- treatment
- receptor
- Prior art date
Links
- 206010037180 Psychiatric symptoms Diseases 0.000 title abstract 2
- USSIQXCVUWKGNF-KRWDZBQOSA-N dextromethadone Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-KRWDZBQOSA-N 0.000 title abstract 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- KYHAUJGXNUJCTC-LPHOPBHVSA-N (3s,6s)-6-(methylamino)-4,4-diphenylheptan-3-ol Chemical compound C=1C=CC=CC=1C(C[C@H](C)NC)([C@@H](O)CC)C1=CC=CC=C1 KYHAUJGXNUJCTC-LPHOPBHVSA-N 0.000 abstract 1
- 229950005506 acetylmethadol Drugs 0.000 abstract 1
- -1 d-alpha-normethadol Chemical compound 0.000 abstract 1
- 229950004655 dimepheptanol Drugs 0.000 abstract 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un método de tratamiento de síntomas psiquiátricos en un sujeto que tiene un receptor de NMDA y un receptor de NE, que incluye administrar d-metadona, d-metadol, d-alfa-acetilmetadol, I-alfa-acetilmetadol, d-alfa-normetadol, I-alfa-normetadol, sales farmacéuticamente aceptables de la misma, o mezclas de la misma al sujeto, bajo condiciones efectivas para que la sustancia se una al receptor de NMDA y al receptor de NE del sujeto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706178P | 2012-09-27 | 2012-09-27 | |
| US13/803,375 US9468611B2 (en) | 2012-09-27 | 2013-03-14 | d-Methadone for the treatment of psychiatric symptoms |
| PCT/US2013/061639 WO2014052427A1 (en) | 2012-09-27 | 2013-09-25 | D-methadone for the treatment of psychiatric symptoms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015006720A true MX2015006720A (es) | 2016-06-28 |
| MX367811B MX367811B (es) | 2019-09-06 |
Family
ID=50339472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006720A MX367811B (es) | 2012-09-27 | 2013-09-25 | D-metadona para el tratamiento de síntomas psiquiátricos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9468611B2 (es) |
| EP (1) | EP2906209B1 (es) |
| KR (2) | KR101969667B1 (es) |
| CN (1) | CN105473135B (es) |
| AU (2) | AU2013323645B2 (es) |
| CA (1) | CA2893238C (es) |
| DK (1) | DK2906209T3 (es) |
| ES (1) | ES2686845T3 (es) |
| HR (1) | HRP20181481T1 (es) |
| HU (1) | HUE039681T2 (es) |
| MX (1) | MX367811B (es) |
| PL (1) | PL2906209T3 (es) |
| PT (1) | PT2906209T (es) |
| RS (1) | RS57724B1 (es) |
| SI (1) | SI2906209T1 (es) |
| WO (1) | WO2014052427A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9682049B2 (en) | 2015-02-18 | 2017-06-20 | Y. Eugene Mironer | Non-racemic mixtures of various ratios of D- and L-methadone and methods of treating pain using the same |
| MA42685A (fr) | 2015-08-24 | 2018-07-04 | Cody Laboratories Inc | Synthèse de chlorhydrate de lévométhadone ou de chlorhydrate de dextrométhadone et leurs méthodes d'utilisation |
| KR20190124722A (ko) * | 2017-01-31 | 2019-11-05 | 파올로 엘. 만프레디 | 신경계 장애의 치료에서 사용하기 위한 ｄ-메타돈 및 이의 유도체 |
| TW202532057A (zh) * | 2017-08-30 | 2025-08-16 | 保羅 L 曼弗雷蒂 | 用於治療或預防神經系統病症及其症狀及表現、以及用於對抗疾病及細胞老化及其症狀及表現之細胞保護之化合物 |
| US12036189B2 (en) | 2018-06-27 | 2024-07-16 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| US11865088B2 (en) | 2018-10-05 | 2024-01-09 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| WO2020075134A1 (en) | 2018-10-11 | 2020-04-16 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| EP4219498A1 (en) | 2019-03-07 | 2023-08-02 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| IL293506A (en) | 2019-12-30 | 2022-08-01 | Clexio Biosciences Ltd | Dosage regime with esketamine for treating major depressive disorder |
| EP4085044A4 (en) * | 2020-01-03 | 2024-06-12 | University of Padova | DEXTROMETHADONE AS A DISEASE MODIFYING THERAPY FOR NEUROPSYCHIATRIC DISORDERS AND DISEASES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596807A (en) * | 1985-03-26 | 1986-06-24 | Serotonin Industries Of Charleston | Method and compositions for controlling pain, depression and sedation |
| CA2278422C (en) * | 1997-01-22 | 2007-11-13 | Cornell Research Foundation, Inc. | D-methadone, a nonopioid analgesic |
| EP1471909A4 (en) * | 2002-01-16 | 2007-07-25 | Endo Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| US8202525B2 (en) * | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
-
2013
- 2013-03-14 US US13/803,375 patent/US9468611B2/en active Active
- 2013-09-25 SI SI201331180T patent/SI2906209T1/sl unknown
- 2013-09-25 WO PCT/US2013/061639 patent/WO2014052427A1/en not_active Ceased
- 2013-09-25 PT PT13773543T patent/PT2906209T/pt unknown
- 2013-09-25 AU AU2013323645A patent/AU2013323645B2/en active Active
- 2013-09-25 DK DK13773543.7T patent/DK2906209T3/en active
- 2013-09-25 EP EP13773543.7A patent/EP2906209B1/en active Active
- 2013-09-25 CN CN201380061197.3A patent/CN105473135B/zh active Active
- 2013-09-25 ES ES13773543.7T patent/ES2686845T3/es active Active
- 2013-09-25 CA CA2893238A patent/CA2893238C/en active Active
- 2013-09-25 KR KR1020177036888A patent/KR101969667B1/ko active Active
- 2013-09-25 HU HUE13773543A patent/HUE039681T2/hu unknown
- 2013-09-25 RS RS20181108A patent/RS57724B1/sr unknown
- 2013-09-25 PL PL13773543T patent/PL2906209T3/pl unknown
- 2013-09-25 MX MX2015006720A patent/MX367811B/es active IP Right Grant
- 2013-09-25 KR KR1020157010922A patent/KR20150085510A/ko not_active Ceased
- 2013-09-25 HR HRP20181481TT patent/HRP20181481T1/hr unknown
-
2016
- 2016-07-07 US US15/204,052 patent/US9855226B2/en active Active
-
2017
- 2017-12-12 AU AU2017276189A patent/AU2017276189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2906209T3 (en) | 2018-10-01 |
| MX367811B (es) | 2019-09-06 |
| KR101969667B1 (ko) | 2019-04-17 |
| US9468611B2 (en) | 2016-10-18 |
| PT2906209T (pt) | 2018-10-16 |
| PL2906209T3 (pl) | 2018-12-31 |
| AU2017276189B2 (en) | 2018-12-06 |
| HUE039681T2 (hu) | 2019-01-28 |
| HK1213797A1 (en) | 2016-07-15 |
| AU2013323645A1 (en) | 2015-05-14 |
| CA2893238C (en) | 2020-11-10 |
| WO2014052427A1 (en) | 2014-04-03 |
| RS57724B1 (sr) | 2018-12-31 |
| CN105473135B (zh) | 2018-09-14 |
| SI2906209T1 (sl) | 2018-11-30 |
| KR20150085510A (ko) | 2015-07-23 |
| HRP20181481T1 (hr) | 2018-11-02 |
| US20160310450A1 (en) | 2016-10-27 |
| AU2013323645B2 (en) | 2017-11-02 |
| CA2893238A1 (en) | 2014-04-03 |
| KR20180001581A (ko) | 2018-01-04 |
| AU2017276189A1 (en) | 2018-01-18 |
| US20140088155A1 (en) | 2014-03-27 |
| EP2906209A1 (en) | 2015-08-19 |
| ES2686845T3 (es) | 2018-10-22 |
| CN105473135A (zh) | 2016-04-06 |
| EP2906209B1 (en) | 2018-06-20 |
| US9855226B2 (en) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015006720A (es) | D-metadona para el tratamiento de sintomas psiquiatricos. | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| PH12015502075B1 (en) | Treatment of cataplexy | |
| MX350745B (es) | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. | |
| EA201790653A1 (ru) | Способ лечения болезни альцгеймера и других расстройств | |
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| MY202135A (en) | Uses of neuroactive compounds | |
| MX356933B (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| MX2018008882A (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX339793B (es) | Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina. | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| SG10201807318RA (en) | Methods for treating chronic obstructive pulmonary disease using benralizumab | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| EA201690327A1 (ru) | Терапевтические способы | |
| PH12014502065A1 (en) | Vesicular formulations | |
| UA113859C2 (xx) | Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX2015000064A (es) | Compuestos de acrilamida como ligandos receptores de histamina h3. | |
| MX354989B (es) | Regimenes de tratamiento. | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2012014971A (es) | Dosis fija de combinacion de sildenafilo y dapoxetina. | |
| MX2013008137A (es) | Procedimientos para tratar la prostatitis. | |
| IN2013MU03427A (es) | ||
| MX355103B (es) | Composicion para el tratamiento de desordenes inflamatorios e inmunes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |